New drug combo shows promise for Hard-to-Treat breast cancer

NCT ID NCT05143229

Ongoing Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests two drugs, alpelisib and sacituzumab govitecan, together in people with advanced HER2-negative breast cancer that has spread or come back. The main goal is to find the safest dose and check for side effects. About 18 adults are taking part in this study at the University of Kansas Medical Center.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
The University of Kansas Cancer Center - Indian Creek

Overland Park, Kansas, 66211, United States
The University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
The University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
The University of Kansas Cancer Center - North Kansas City Hospital

Kansas City, Missouri, 64116, United States
The University of Kansas Cancer Center - Overland Park

Overland Park, Kansas, 66210, United States
The University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.